Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04245930
Other study ID # E2019453
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 1, 2020
Est. completion date December 31, 2022

Study information

Verified date January 2020
Source Tianjin Medical University Cancer Institute and Hospital
Contact Chunyong Han, MD.
Phone +86-22-23340123
Email hancy_007@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is the first randomized and controlled study assessing the efficacy and safety of bovine pericardial patch and TiLOOP® bra mesh in patients with immediate implant breast reconstruction


Recruitment information / eligibility

Status Recruiting
Enrollment 176
Est. completion date December 31, 2022
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

1. Patients diagnosed with I~II stage breast cancer and Intent to receive NSM or SSM and implant based breast reconstruction

2. Do not smoking in the last 4 weeks or more

3. Mental health patients

4. Signed consent to participate

Exclusion Criteria:

1. Locally advanced stage patients or patients with distal metastasis

2. Patients received thoracic wall radiotherapy or will receive radiotherapy

3. Smoking in the last 4 weeks

4. Anticipated implant volume more than 600cc

5. Patients of pregnancy or lactation

6. Patients received neoadjuvant therapy

Study Design


Intervention

Procedure:
Bovine Pericardial Patch in Immediate Implant Breast Reconstruction
Patients will receive immediate breast implant reconstruction using Bovine Pericardial Patch
TiLOOP® Bra Mesh in Immediate Implant Breast Reconstruction
Patients will receive immediate breast implant reconstruction using TiLOOP® Bra Mesh

Locations

Country Name City State
China Tianjin Medical University Cancer Institute and Hospital Tianjin Tianjin

Sponsors (1)

Lead Sponsor Collaborator
Tianjin Medical University Cancer Institute and Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Complication Rates The rate of complications in the two groups up to 12 months after surgery
Secondary Patient satisfaction-Breast-Q questionnaire We use the Breast-Q questionnaire to evaluate patients' satisfaction via the reconstruction module of BREAST-Q. up to 12 months after surgery
Secondary Cosmetic outcome of reconstructed breast Harris evaluation score was used to evaluate the aesthetic outcome of patients' reconstructed breasts, which was scored as "excellent," "good," "fair," "poor". Immediately, up to 3 months, 6 months and 12 months after surgery
Secondary The rate of surgical revision of reconstructed breasts To record the rate of surgical revision events of the reconstructed breasts up to 12 months after surgery
Secondary Health economics-inpatient cost Hospital inpatient costs due to immediate implant breast reconstruction up to 12 months after surgery, including the cost of surgical revision
See also
  Status Clinical Trial Phase
Recruiting NCT05992870 - Neoadjuvant Radiotherapy and Immediate Implant-Based Breast Reconstruction N/A